- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Crispr Therapeutics AG (CRSP)
Assess today's live Crispr Therapeutics AG (CRSP) share price, performance and insights using our live NASDAQ: CRSP stock exchange data.
Analyse the historical data and Crispr Therapeutics AG share price performance charts on this page. Our technical summary section provides analysis on Crispr Therapeutics share price buy/sell indicators using real-time data (or discuss the Crispr Therapeutics (CRSP) stock price today with other investors in the Crispr Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ CRSP share price (ISIN: CH0334081137) to enhance your trading decisions with our free investment tools and resources.
What Is the Crispr Therapeutics AG Share Price Today?
The Crispr Therapeutics share price today is 41.03.
What Is the Stock Symbol for Crispr Therapeutics AG
The stock symbol (or 'ticker') for Crispr Therapeutics AG is "CRSP."
What Stock Exchange Does Crispr Therapeutics AG Trade On?
Crispr Therapeutics AG is listed and trades on the NASDAQ stock exchange.
Is Crispr Therapeutics AG a Good Stock to Buy?
Determining whether Crispr Therapeutics AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Crispr Therapeutics AG share price performance charts on this page. Our technical summary section provides analysis on Crispr Therapeutics share price buy/sell indicators using real-time data (or discuss the Crispr Therapeutics (CRSP) stock price today with other investors in the Crispr Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ CRSP share price (ISIN: CH0334081137) to enhance your trading decisions with our free investment tools and resources.
What Is the Crispr Therapeutics AG Share Price Today?
The Crispr Therapeutics share price today is 41.03.
What Is the Stock Symbol for Crispr Therapeutics AG
The stock symbol (or 'ticker') for Crispr Therapeutics AG is "CRSP."
What Stock Exchange Does Crispr Therapeutics AG Trade On?
Crispr Therapeutics AG is listed and trades on the NASDAQ stock exchange.
Is Crispr Therapeutics AG a Good Stock to Buy?
Determining whether Crispr Therapeutics AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
41.03
-0.25(-0.61%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
40.00
41.08
52 wk Range
30.04
65.39
CRSP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CRSP is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
40.0041.08
52 wk Range
30.0465.39
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRSP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
81.67
Upside
+99.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
10 analysts have revised their earnings downwards for the upcoming period
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Crispr Therapeutics AG SWOT Analysis
Pioneering Gene Therapy | CRISPR Therapeutics leads with Casgevy, a groundbreaking treatment for sickle cell disease and β-thalassemia, marking a new era in genetic medicine |
Pipeline Potential | Explore CRISPR's diverse clinical programs, including promising CAR-T therapies for cancer and autoimmune diseases, showcasing the platform's versatility |
Financial Health | With $1.9 billion in cash and analyst price targets ranging from $53 to $105, CRISPR balances strong liquidity against the costs of innovation |
Market Challenges | Delve into CRISPR's strategy to navigate a competitive landscape, regulatory hurdles, and the complexities of commercializing cutting-edge gene therapies |
Compare CRSP to Peers and Sector
Metrics to compare | CRSP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRSPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.8x | −1.6x | −0.5x | |
PEG Ratio | 0.15 | 0.01 | 0.00 | |
Price/Book | 2.1x | 1.1x | 2.6x | |
Price / LTM Sales | 100.5x | 4.1x | 3.1x | |
Upside (Analyst Target) | 93.8% | 118.0% | 48.3% | |
Fair Value Upside | Unlock | 5.5% | 7.6% | Unlock |
Analyst Ratings
17 Buy
10 Hold
1 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 81.67
(+99.04% Upside)
Earnings
Latest Release
May 06, 2025
EPS / Forecast
-1.58 / -1.21
Revenue / Forecast
860.00K / 7.10M
People Also Watch
FAQ
What Is the Crispr Therapeutics (CRSP) Stock Price Today?
The Crispr Therapeutics stock price today is 41.03
What Stock Exchange Does Crispr Therapeutics Trade On?
Crispr Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Crispr Therapeutics?
The stock symbol for Crispr Therapeutics is "CRSP."
What Is the Crispr Therapeutics Market Cap?
As of today, Crispr Therapeutics market cap is 3.79B.
What Is Crispr Therapeutics's Earnings Per Share (TTM)?
The Crispr Therapeutics EPS (TTM) is -4.52.
When Is the Next Crispr Therapeutics Earnings Date?
Crispr Therapeutics will release its next earnings report on 10 Aug 2025.
From a Technical Analysis Perspective, Is CRSP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Crispr Therapeutics Stock Split?
Crispr Therapeutics has split 0 times.
How Many Employees Does Crispr Therapeutics Have?
Crispr Therapeutics has 393 employees.
What is the current trading status of Crispr Therapeutics (CRSP)?
As of 13 Jun 2025, Crispr Therapeutics (CRSP) is trading at a price of 41.03, with a previous close of 41.28. The stock has fluctuated within a day range of 40.00 to 41.08, while its 52-week range spans from 30.04 to 65.39.
What Is Crispr Therapeutics (CRSP) Price Target According to Analysts?
The average 12-month price target for Crispr Therapeutics is USD81.66667, with a high estimate of USD268 and a low estimate of USD32. 17 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +99.04% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.